A germline pathogenic variant in was secondarily found through genomic sequencing of uterine serous carcinoma. Clinical response to olaparib was observed in recurrent uterine serous carcinoma with a germline mutation. Here, we report, for the first time, a long-term clinical response to olaparib in a patient with uterine serous carcinoma and a germline pathogenic variant.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152717 | PMC |
| http://dx.doi.org/10.1016/j.gore.2020.100563 | DOI Listing |
Publication Analysis
Top Keywords
uterine serous
16
serous carcinoma
16
carcinoma germline
12
germline pathogenic
12
pathogenic variant
12
recurrent uterine
8
clinical response
8
response olaparib
8
serous
4
carcinoma
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!